UNSPSC 51152018: Butamisole

This classification denotes an antihelminthic agent with the molecular formula C15H19N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XVB7982801, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thiazol-6-yl)phenyl)-, (-)- but generally known as butamisole, which bears US NIH Compound Identifier 166572. Butamisole most often comes in base and hydrochloride forms. European Medicines Agency schedules Butamisole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06001MIG.

UNSPSC 51152018 Butamisole is a Commodity code that nominally addresses a specific veterinary and anthelmintic pharmaceutical, but recent state and local procurement activity under this code does not reflect purchases of butamisole itself. Instead, the code is being applied to broader pharmaceutical and health-related procurements, chiefly naloxone (a life-saving opioid antagonist) and related drug-intervention systems. Seminole County, Florida posted an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a two-year initial term plus one-year renewal option. The work involves straightforward commodity procurement with fixed-fee pricing, vendor insurance and compliance requirements, and potential FEMA funding. Issuing bodies soliciting under this code span county health departments and state health agencies; Seminole County and the Texas Health and Human Services Commission are the primary recent actors. Neither solicitation shows explicit set-aside or disadvantaged-enterprise designations.

Geographic activity centers on Florida and Texas based on the recent record. Seminole County's naloxone IFB (due July 26, 2023) targets the Seminole County Community Health Building in Sanford, Florida with electronic bid submission. Texas HHS issued an RFI in April 2026 (posted April 3, due April 3) to gather vendor capability information on direct-to-manufacturer pharmacy prescription programs for state self-insured employee health plans and government agencies. The Texas RFI is exploratory and precedes formal competitive solicitation; it seeks vendor experience with direct contracting outside traditional pharmacy benefit managers and wholesaler channels, flexibility on net-pricing models, and value-based contracting capability. The mismatch between the code's nominal scope (butamisole) and actual recent procurement (naloxone systems and pharmacy benefit programs) suggests this code may be misapplied in state and local systems, and pursuit should be grounded in actual recent demand signals rather than the code name.